The potential of selective progesterone receptor modulators for the treatment of uterine fibroids

References

• Cramer SF, Patel A. The frequency of uterine leiomyomas. Am. J. Clin. Pathol. 94(4), 435–438 (1990).
   PubMed Web of Science ®Google Scholar
• Marshall LM, Spiegelman D, Barbieri RL et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet. Gynecol. 90(6), 967–973 (1997).
   PubMed Web of Science ®Google Scholar
• Vollenhoven B. Introduction: the epidemiology of uterine leiomyomas. Baillieres Clin. Obstet. Gynaecol. 12(2), 169–176 (1998).
   Google Scholar
• Baird D.D., Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am. J. Obstet. Gynecol. 188(1), 100–107 (2003).
   PubMed Web of Science ®Google Scholar
• Stewart EA. Uterine fibroids. Lancet 357(9252), 293–298 (2001).
   PubMed Web of Science ®Google Scholar
• Williams VSL, Jones G, Mauskopf J, Spalding J, DuChane J. Uterine fibroids: a review of health-related quality of life assessment. J. Womens Health 15(7), 818–829 (2006).
   PubMed Web of Science ®Google Scholar
• Cote I, Jacobs P, Cumming D. Work loss associated with increased menstrual loss in the United States. Obstet. Gynecol. 100(4), 683–687 (2002).
   PubMed Web of Science ®Google Scholar
• Hartmann KE, Birnbaum H, Ben-Hamadi R et al. Annual costs associated with diagnosis of uterine leiomyomata. Obstet. Gynecol. 108(4), 930–937 (2006).
   Google Scholar
• Becker ER, Spalding J, DuChane J, Horowitz IR. Inpatient surgical treatment patterns for patients with uterine fibroids in the United States, 1998–2002. J. Natl Med. Assoc. 97(10), 1336–1342 (2005).
   Google Scholar
• Nisolle M, Gillerot S, Casanas-Roux F, Squifflet J, Berliere M, Donnez J. Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy. Hum. Reprod. 14(11), 2844–2850 (1999).
   PubMed Web of Science ®Google Scholar
• Afhuppe W, Sommer A, Muller J, Schwede W, Fuhrmann U, Moller C. Global gene expression profiling of progesterone receptor modulators in T47D cells provides a new classification system. J. Steroid. Biochem. Mol. Biol. 113(1–2), 105–115 (2009).
   PubMed Web of Science ®Google Scholar
• Attardi BJ, Burgenson J, Hild SA, Reel JR, Blye RP. CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Mol. Cell Endocrinol. 188(1–2), 111–123 (2002).
   PubMed Web of Science ®Google Scholar
• Chwalisz K, Garg R, Brenner R, Slayden O, Winkel C, Elger W. Role of nonhuman primate models in the discovery and clinical development of selective progesterone receptor modulators (SPRMs). Reprod. Biol. Endocrinol. 4( Suppl. 1), S8 (2006).
   PubMedGoogle Scholar
• Catherino WH, Malik M, Driggers P, Chappel S, Segars J, Davis J. Novel, orally active selective progesterone receptor modulator CP8947 inhibits leiomyoma cell proliferation without adversely affecting endometrium or myometrium. J. Steroid. Biochem. Mol. Biol. 122(4), 279–286 (2010).
   Google Scholar
• Chabbert-Buffet N, Pintiaux A, Bouchard P. The immninent dawn of SPRMs in obstetrics and gynecology. Mol. Cell Endocrinol. 358(2), 232–243 (2012).
   Google Scholar
• Madauss KP, Grygielko ET, Deng SJ et al. A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator. Mol. Endocrinol. 21(5), 1066–1081 (2007).
   PubMed Web of Science ®Google Scholar
• Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum. Reprod. Update 11(3), 293–307 (2005).
   PubMed Web of Science ®Google Scholar
• Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol. Endocrinol. 11(6), 693–705 (1997).
   PubMed Web of Science ®Google Scholar
• Liu Z, Auboeuf D, Wong J et al. Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486. Proc. Natl Acad. Sci. USA 99(12), 7940–7944 (2002).
   Google Scholar
• Spitz IM. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr. Opin. Obstet. Gynecol. 21(4), 318–324 (2009).
   PubMed Web of Science ®Google Scholar
• Brandon DD, Bethea CL, Strawn EY et al. Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am. J. Obstet. Gynecol. 169(1), 78–85 (1993).
   Google Scholar
• Viville B, Charnock-Jones DS, Sharkey AM, Wetzka B, Smith SK. Distribution of the A and B forms of the progesterone receptor messenger ribonucleic acid and protein in uterine leiomyomata and adjacent myometrium. Hum. Reprod. 12(4), 815–822 (1997).
   Google Scholar
• Xu Q, Takekida S, Ohara N et al. Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5’-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells. J. Clin. Endocrinol. Metab. 90(2), 953–961 (2005).
   PubMed Web of Science ®Google Scholar
• Horne FM, Blithe DL. Progesterone receptor modulators and the endometrium: changes and consequences. Hum. Reprod. Update 13(6), 567–580 (2007).
   Google Scholar
• Rein MS, Barbieri RL, Friedman AJ. Progesterone: a critical role in the pathogenesis of uterine myomas. Am. J. Obstet. Gynecol. 172(Pt 1), 14–18 (1995).
   Google Scholar
• Slayden OD, Nayak NR, Burton KA et al. Progesterone antagonists increase androgen receptor expression in the rhesus macaque and human endometrium. J. Clin. Endocrinol. Metab. 86(6), 2668–2679 (2001).
   Google Scholar
• Brenner RM, Slayden OD, Critchley HO. Anti-proliferative effects of progesterone antagonists in the primate endometrium: a potential role for the androgen receptor. Reproduction 124(2), 167–172 (2002).
   Google Scholar
• Maruo T, Ohara T, Wang J, Matsuo H. Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum. Reprod. Update 10(3), 207–220 (2004).
   PubMed Web of Science ®Google Scholar
• Slayden OD , Brenner RM. Flutamide counteracts the antiproliferative effects of antiprogestins in the primate endometrium. J. Clin. Endocrinol. Metab. 88(2), 946–949 (2003).
   Google Scholar
• Lumsden MA, West CP, Bramley T, Rumgay L, Baird DT. The binding of epidermal growth factor to the human uterus and leiomyomata in women rendered hypo-oestrogenic by continuous administration of an LHRH agonist. Br. J. Obstet. Gynaecol. 95(12), 1299–1304 (1988).
   PubMedGoogle Scholar
• Maruo T, Matsuo H,Shimomura Y, Kurachi O, Gao Z, Nakago S,Yamada T, Chen W, Wang J. Effects of progesterone on growth factor expression in human uterine leiomyoma. Steroids 68(10–13), 817–824 (2003).
   Google Scholar
• Kettel LM, Murphy AA, Morales AJ, Yen SS. Clinical efficacy of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids. Hum. Reprod. 9( Suppl. 1), 116–120 (1994).
   PubMed Web of Science ®Google Scholar
• Chen W, Ohara N, Wang J et al. A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J. Clin. Endocrinol. Metab. 91(4), 1296–1304 (2006).
   PubMed Web of Science ®Google Scholar
• Luo X, Yin P, Coon VJ, Cheng YH, Wiehle RD, Bulun SE. The selective progesterone receptor modulator CDB4124 inhibits proliferation and induces apoptosis in uterine leiomyoma cells. Fertil. Steril. 93(8), 2668–2673 (2010).
   PubMed Web of Science ®Google Scholar
• Morikawa A, Ohara N, Xu Q et al. Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducer. Hum. Reprod. 23(4), 944–951 (2008).
   Google Scholar
• Koji T, Chedid M, Rubin JS et al. Progesterone-dependent expression of keratinocyte growth factor mRNA in stromal cells of the primate endometrium: keratinocyte growth factor as a progestomedin. J. Cell Biol. 125(2), 393–401 (1994).
   Google Scholar
• Wang J, Ohara N, Wang Z et al. A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells. Hum. Reprod. 21(7), 1869–1877 (2006).
   Google Scholar
• Xu Q, Ohara N, Wei C et al. Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor,adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells. Hum. Reprod. 21(9), 2408–2416 (2006).
   PubMed Web of Science ®Google Scholar
• Horak P, Mara M, Dundr P et al. Effect of a selective progesterone receptor modulator on induction of apoptosis in uterine fibroids in vivo. Int. J. Endocrinol. 2012, 436174 (2012).
   PubMed Web of Science ®Google Scholar
• Reinsch RC, Murphy AA, Morales AJ, Yen SS. The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study. Am. J. Obstet. Gynecol. 170(6), 1623–1627 (1994).
   PubMed Web of Science ®Google Scholar
• Wilkens J, Chwalisz K. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J. Clin. Endocrinol. Metab. 93(12), 4664–4671 (2008).
   Google Scholar
• Chwalisz K, Larsen L, Mattia-Goldberg C, Edmonds A, Elger W, Winkel CA. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil. Steril. 87(6), 1399–1412 (2007).
   PubMed Web of Science ®Google Scholar
• Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of the progesterone receptor modulator VA2914 in a continuous low-dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab. 92(9), 3582–3589 (2007).
   PubMed Web of Science ®Google Scholar
• Bouchard P, Chabbert-Buffet N, Fauser BC. Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil. Steril. 96(5), 1175–1189 (2011).
   PubMed Web of Science ®Google Scholar
• Brache V, Cochon L, Jesam C et al. Immediate pre-ovulatory administration of 30 mg ulipristal acetate significantly delays follicular rupture. Hum. Reprod. 25(9), 2256–2263 (2010).
   PubMedGoogle Scholar
• Liu JH, Garzo G, Morris S, Stuenkel C, Ulmann A, Yen SS. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486. J. Clin. Endocrinol. Metab. 65(6), 1135–1140 (1987).
   Google Scholar
• Reel JR, Humphrey RR, Shih YH, Windsor BL, Sakowski R, Creger PL, Edgren RA. Antiovulatory and postcoital antifertility activity of the antiprogestin CDB-2914 when administered as single, multiple, or continuous doses to rats. Contraception 58, 129–136 (1998).
   PubMed Web of Science ®Google Scholar
• Stratton P, Hartog B, Hajizadeh N et al. A single mid-follicular dose of CDB-2914, a new antiprogestin, inhibits folliculogenesis and endometrial differentiation in normally cycling women. Hum.Reprod. 15(5), 1092–1099 (2000).
   PubMed Web of Science ®Google Scholar
• Chwalisz K, Elger W, Stickler T, Mattia-Goldberg C, Larsen L. The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women. Hum. Reprod. 20(4), 1090–1099 (2005).
   PubMed Web of Science ®Google Scholar
• Mutter GL, Bergeron C, Deligdisch L et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod.Pathol. 21(5), 591–598 (2008).
   PubMed Web of Science ®Google Scholar
• Eisinger SH, Bonfiglio T, Fiscella K, Meldrum S, Guzick DS. 12-month safety and efficacy of low-dose mifepristone for uterine myomas. J. Minim. Invasive. Gynecol. 12(3), 227–233 (2005).
   Web of Science ®Google Scholar
• Williams AR, Bergeron C, Barlow DH, Ferenczy A. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Int. J. Gynecol. Pathol. 31(6), 556–569 (2012).
   PubMed Web of Science ®Google Scholar
• Croxatto HB, Kovacs L, Massai R et al. Effects of long-term low-dose mifepristone on reproductive function in women. Hum. Reprod. 13(4), 793–798 (1998).
   PubMed Web of Science ®Google Scholar
• Eisinger SH, Meldrum S, Fiscella K, le Roux HD, Guzick DS. Low-dose mifepristone for uterine leiomyomata. Obstet. Gynecol. 101(2), 243–250 (2003).
   Google Scholar
• Engman M, Granberg S, Williams AR, Meng CX, Lalitkumar PG, Gemzell-Danielsson K. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum. Reprod. 24(8), 1870–1879 (2009).
   Google Scholar
• Wiehle R. Effects of a new progesterone receptor modulator, CDB-4124, on fibroid size and uterine bleeding. US Obstet. Gynecol. 17–20 (2008).
   Google Scholar
• Chwalisz K, Perez MC, Demanno D, Winkel C, Schubert G, Elger W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr. Rev. 26(3), 423–438 (2005).
   PubMed Web of Science ®Google Scholar
• Bagaria M, Suneja A, Vaid NB, Guleria K, Mishra K. Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial. Aust. N. Z. J. Obstet. Gynaecol. 49(1), 77–83 (2009).
   Web of Science ®Google Scholar
• Fiscella K, Eisinger SH, Meldrum S, Feng C, Fisher SG, Guzick DS. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet. Gynecol. 108(6), 1381–1387 (2006).
   Google Scholar
• Carbonell JL, Acosta R, Perez Y et al. mifepristone versus placebo to treat uterine myoma: a double-blind, randomized clinical trial. Int. J. Womens Health 5, 361–369 (2013).
   Google Scholar
• Levens ED, Potlog-Nahari C, Armstrong AY et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet. Gynecol. 111(5), 1129–1136 (2008).
   PubMed Web of Science ®Google Scholar
• Nieman LK, Blocker W, Nansel T et al. Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study. Fertil. Steril. 95(2), 767–772 (2011).
   PubMed Web of Science ®Google Scholar
• Donnez J, Tatarchuk TF, Bouchard P et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N. Engl. J. Med. 366(5), 409–420 (2012).
   PubMed Web of Science ®Google Scholar
• Donnez J, Tomaszewski J, Vazquez F et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N. Engl. J. Med. 366(5), 421–432 (2012).
   PubMed Web of Science ®Google Scholar
• Higham JM, O’Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br. J. Obstet. Gynaecol. 97(8), 734–739 (1990).
   PubMedGoogle Scholar
• Klijn JG, Setyono-Han B, Foekens JA. Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids 65(10–11), 825–830 (2000).
   Google Scholar
• Bouchard P. Current and future medical treatments for menometrorrhagia duringthe premenopause. Gynecol. Endocrinol. 27(S1), 1120–1121 (2011).
   Google Scholar
• Murphy AA, Kettel LM, Morales AJ, Roberts VJ, Yen SS. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J. Clin. Endocrinol. Metab 76(2), 513–517 (1993).
   PubMed Web of Science ®Google Scholar
• Carbonell JL, Acosta R, Perez Y et al. Safety and effectiveness of different dosage of mifepristone for the treatment of uterine fibroids: a double-blind randomized clinical trial. Int. J. Womens Health 5, 115–124 (2013).
   PubMedGoogle Scholar
• Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314(5804), 1467–1470 (2006).
   PubMed Web of Science ®Google Scholar
• Wiehle R, Lantvit D, Yamada T, Christov K. CDB-4124, a Progesterone receptor modulator, inhibits mammary carcinogenesis by suppressing cell proliferation and inducing apoptosis. Cancer Prev. Res. (Phila) 4(3), 414–424 (2011).
   Google Scholar
• Communal L, Vilasco M, Hugon-Rodin J et al. Ulipristal acetate does not impact human normal breast tissue. Hum. Reprod. 27(9), 2785–2798 (2012).
   Google Scholar
• Carbonell Esteve JL, Acosta R, Heredia B, Perez Y, Castaneda MCY, Valle Hernandez A. Mifepristone for the treatment of uterineleiomyomas. A randomized controlled trial. Obstet. Gynecol.112(5), 1029–1036 (2008).
   Google Scholar
• Eisinger SH, Fiscella J, Bonfiglio T, Meldrum S, Fiscella K. Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata. Eur. J. Obstet. Gynecol. Reprod. Biol. 146(2), 215–218 (2009).
   Web of Science ®Google Scholar
• Esteve JL, Acosta R, Perez Y, Campos R, Valle Hernandez A, Texido CS. Treatment of uterine myoma with 5 or 10 mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trial. Eur. J. Obstet. Gynecol. Reprod. Biol. 161(2), 202–208(2012).
   Google Scholar
• Carbonell Esteve JL, Riveron AM, Cano M Ortiz AI, Valle A, Texido CS, Tomasi G. Mifepristone 2.5 mg versus 5 mg dailyin the treatment of leiomyoma before surgery. Int. J. Womens Health 4, 75–84 (2012).
   PubMedGoogle Scholar
• Carbonell JL, Acosta R, Perez Y, Garces R, Sanchez C, Tomasi G. Treatment of uterine myoma with 2.5 or 5mg mifepristone daily during 3 months with 9 months posttreatment follow-up: randomized clinical trial. ISRN Obstet. Gynecol. 1–8 (2013).
   Google Scholar
• Leonardt SA, Edwards DP. Mechanism of action of progesterone antagonists. Exp. Biol. Med. 227(11), 969–980 (2002).
   Google Scholar